FindTrial
Sign In

Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?

DIETary Strategies to stabiLize Incretin-based Weight Loss in Obesity Management

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07711548
Acronym
DIET-SLIM
Enrollment
292
Registered
2026-07-17
Start date
2027-03-01
Completion date
2030-04-01
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity & Overweight, Weight Loss Maintenance

Keywords

Semaglutide, Obesity, Overweight, Diet, Weight loss maintenance

Brief summary

So far, treatment with semaglutide (Wegovy) for therapy of obesity demonstrates substantial effects. However, most patients do not desire life-long pharmaceutical therapy or discontinue this treatment regime. This is accompanied by rapid weight regain. Moreover, numerous patients are open to an intermittent therapy. This trial aims to investigate whether two diet interventions can keep weight stable after weight loss with semaglutide in people with obesity or overweight.

Interventions

BEHAVIORALNutriAct plus

Dietary pattern, vegetarian version of the NutriAct pattern

BEHAVIORALRescue VLCD

Very low calorie diet as full meal replacement over 28 days in case of weight regain

Sponsors

Knut Mai
Lead SponsorOTHER
University of Latvia
CollaboratorOTHER
Institute for Clinical and Experimental Medicine
CollaboratorOTHER_GOV
University of Vienna
CollaboratorOTHER
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)
CollaboratorUNKNOWN
Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE)
CollaboratorUNKNOWN
German Federal Ministry of Research, Technology, and Space (BMFTR)
CollaboratorUNKNOWN
Austrian Science Fund (FWF)
CollaboratorOTHER
Czech Health Research Council
CollaboratorUNKNOWN
Latvian Council of Science
CollaboratorUNKNOWN
Ministry of Health, Czech Republic
CollaboratorOTHER_GOV
DLR Project Management Agency (DLR)
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* BMI ≥ 30 kg/m² OR ≥ 27 kg/m² with concomitant cardiometabolic risk factors (metabolic syndrome, elevated blood pressure, dyslipidemia or impaired glucose metabolism (but not type 2 diabetes)

Exclusion criteria

* BMI ≥ 45 kg/m² * intake of glucose lowering drugs * presence of incretin-based treatment * acute severe CVD * uncontrolled hypertension * severe hepatic or renal diseases * severe food allergy or malabsorption disease * active cancer * condition after bariatric surgery * history of eating disorder * concurrent pregnancy and breastfeeding

Design outcomes

Primary

MeasureTime frame
weight in kgbody weight in kg after weight loss (3 to 5 months) and dietary intervention (12 months)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 21, 2026